Publications

Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S

Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nature Biomedical Engineering, 2023 Jan;7(1):24-37.

Ishikawa A, Waseda M, Ishii T,Kaneko K. M, Kato Y, Kaneko S.

Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in an animal model. Genes to Cells, 2022 Sep;27(9):549-558.

Yohei Kawai, Ai Kawana-Tachikawa, Shuichi Kitayama, Tatsuki Ueda, Shoji Miki, Akira Watanabe, Shin Kaneko

Generation of highly proliferative rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy. Mol Ther., 2021 Oct 6;29(10):3027-3041. doi: 10.1016/j.ymthe.2021.05.016. Epub 2021 May 21.

Takeshi Ito, Yohei Kawai, Yutaka Yasui, Shoichi Iriguchi, Atsutaka Minagawa, Tomoko Ishii, Hiroyuki Miyoshi, M. Mark Taketo, Kenji Kawada, Kazutaka Obama, Yoshiharu Sakai, Shin Kaneko

The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-derived iPS cells. Commun Biol., 2021 Jun 7;4(1):694. doi: 10.1038/s42003-021-02195-x.

Bo Wang, Shoichi Iriguchi, Masazumi Waseda, Norihiro Ueda, Tatsuki Ueda, Huaigeng Xu, Atsutaka Minagawa, Akihiro Ishikawa, Hisashi Yano, Tomoko Ishi, Ryoji Ito, Motohito Goto, Riichi Takahashi,Yasushi Uemura, Akitsu Hotta, and Shin Kaneko

Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells Nature Biomedical Engineering, 2021 May;5(5):429-440.

Iwamoto Y, Seki Y, Taya K, Tanaka M, Iriguchi S, Miyake Y, Nakamura E. E, Miura T, Shioda T, Akari H, Takaori-Kondo A, Kaneko S.

Generation of macrophages with altered viral sensitivity from genomeedited rhesus macaque iPSCs to model human disease Molecular Therapy - Methods & Clinical Development, 21:262+273 (2021)

Mashima H, Zhang R, Kobayashi T, Tsukamoto H, Liu T, Iwama T, Hagiya Y, Yamamoto M, Fukushima S, Okada S, Idiris A, Kaneko S, Nakatsura T, Ohdan H, Uemura Y.

Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy. Molecular Therapy - Methods & Clinical Development, 21:171-179 (2021)

Ishigaki H, Pham VL, Terai J, Sasamura T, Nguyen CT, Ishida H, Okahara J, Kaneko S, Shiina T, Nakayama M, Itoh Y, Ogasawara K.

No Tumorigenicity of Allogeneic Induced Pluripotent Stem Cells in Major Histocompatibility Complex-matched Cynomolgus Macaques. Cell Transplant, 30:1-12 (2021)

Iriguchi s, Yasui Y, Kawai Y, Arima S, Kunitomo M, Sato T, Ueda T, Minagawa A, Mishima Y, Yanagawa N, Baba Y, Miyake Y, Nakayama K, Takiguchi M, Shinohara T, Nakatsura T, Yasukawa M, Kassai Y, Hayashi A, Kaneko S.

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nature Communications, 12(1):430 (2021)

Kazuki Y, Uno N, Abe S, Kajitani N, Kazuki K, Yakura Y, Sawada C, Takata S, Sugawara M, Nagashima Y, Okada A, Hiratsuka M, Osaki M, Ferrari G, Tedesco FS, Nishikawa S, Fukumoto K, Takayanagi SI, Kunisato A, Kaneko S, Oshimura M, Tomizuka K.

Engineering of human induced pluripotent stem cells via human artificial chromosome vectors for cell therapy and disease modeling. Mol Ther Nucleic Acids, 23:629-639 (2020)

Koga K, Wang B, Kaneko S.

Current status and future perspectives of HLA-edited induced pluripotent stem cells. Inflammation and Regeneration, 40(23):40:23 (2020)

Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, Nakane K, Saito K, Takahashi M, Sasaki A, Yoshida S, Takasu N, Seno H, Uemura Y, Tamada K, Nakatsura T, Kaneko S.

Non‐clinical efficacy, safety, and stable clinical cell processing of iPSC‐derived anti‐GPC3 CAR‐expressing NK/ILC cells. Cancer Science, 111(5):1478-1490 (2020)

Zhang R, Kitayama S, Liu T, Ueda N, Tokumitsu Y, Mashima H, Ohdan H, Kaneko S, Uemura Y.

In Vitro Detection of Cellular Adjuvant Properties of Human Invariant Natural Killer T Cells. Methods Mol Biol., 2048:121-130 (2019)

Iriguchi S, Kaneko S.

In Vitro Differentiation of T Cells: From Nonhuman Primate-Induced Pluripotent Stem Cells Methods Mol Biol., 2048:93-106 (2019)

Ueda T, Kaneko S.

In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC. Methods Mol Biol., 2048:85-91 (2019)

Minagawa A, Kaneko S.

Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy. Methods Mol Biol., 2048:81-84 (2019)

Yasui Y, Hitoshi Y, Kaneko S.

In Vitro Differentiation of T Cell: From Human iPS Cells in Feeder-Free Condition. Methods Mol Biol., 2048:77-80 (2019)

Kawai Y, Kaneko S.

Redifferentiation of Adaptive Naïve-Like CTL from T-Cell-Derived iPSC. Methods Mol Biol., 2048:71-75 (2019)

Iriguchi S, Kaneko S.

In Vitro Differentiation of T Cells: From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. Methods Mol Biol., 2048:59-70 (2019)

Radulovic V, van der Garde M, Koide S, Sigurdsson V, Lang S, Kaneko S, Miharada K.

Junctional Adhesion Molecule 2 Represents a Subset of Hematopoietic Stem Cells with Enhanced Potential for T Lymphopoiesis. Cell Report, 27(10):2826-2836.e5. (2019)

Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, Kitaoka F, Takahashi T, Okita K, Yoshida Y, Kaneko S, Hotta A.

Targeted Disruption of HLA genes via CRISPR-Cas9 generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 24(4):566-578.E7, April 4, 2019 (Published: March 7, 2019)

Torisawa Y, Mishima Y, Kaneko S.

Developing thymus-on-a-chip and cancer-on-a-chip for cancer immunotherapy. Impact. 29(2):33-35(3), 2019. doi: 10.1016/j.stem.2019.02.00.

Iriguchi S, Kaneko S.

Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy. Cancer Science. 110(1):16-22, 2018.

Minagawa A, Yoshikawa T, YasukawaT, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.

Enhancing T cell Receptor Stability in Rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell. 23(6):850-858, 2018. doi: 10.1016/j.stem.2018.10.005.

Higaki K, Hirao M, Kawana-Tachikawa A, Iriguchi S, Kumagai A, Ueda N, Bo W, Kamibayashi S, 　Watanabe A, Nakauchi H, Suzuki K, Kaneko S.

Generation of HIV-Resistant Macrophages from iPSCs by Using Transcriptional Gene Silencing and Promoter-Targeted RNA. Molecular Therapy Nucleic Acids. 12(7):793-804, 2018. doi: 10.1016/j.omtn.2018.07.017.

Lee S, Huh JY, Turner D, Lee S, Robinson J, Stein J, Shim SH, Hong CP, Kang MS, Nakagawa M, Kaneko S, Rao M, Kurtz A, Stacey G, Marsh S, Turner M, Song J.

Repurposing the Cord Blood Bank for Haplobanking of HLA-Homozygous iPSCs and Their Usefulness to Multiple Populations. Stem Cells. 36(10):1552-1566,2018. doi: 10.1002/stem.2865

Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, and Kaneko S.

Regeneration of TCR expressing Innate Lymphoid helper cells that induces cytotoxic T cell-mediated anti-leukemic immunity in HLA Class II and bcr-abl peptide restriction. Stem Cell Reports. 10(6):1935-1946, 2018. doi: 10.1016/j.stemcr.2018.04.025.

Oshima K, Saiki N, Tanaka M, Imamura H, Niwa A, Tanimura A, Nagahashi A, Hirayama A, Okita K, Hotta A, Kitayama S, Osawa M, Kaneko S, Watanabe A, Asaka I, Fujibuchi W, Imai K, Yabe H, Kamachi Y, Hara J, Kojima S, Tomita M, Soga T, Noma T, Nonoyama S, Nakahata T, Saito MK.

Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors. Biochem Biophys Res Commun. 2018, 497(2), 719-725, doi: 10.1016/j.bbrc.2018.02.139.

Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.

BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. Cell Mol Immunol. 2016 May 16.

Kaneko S.

In Vitro Generation of Antigen-Specific T Cells from Induced Pluripotent Stem Cells of Antigen-Specific T Cell Origin. Methods Mol Biol. 01 April 2016.

Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T.

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate. Int J Oncol. 2016 May;48(5):1794-804.

Kitayama S, Zhang R, Tian-Yi Liu, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, Iwama T, Watanabe A, Nakanishi M, Kuzushima K, Uemura Y, and Kaneko S.

Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Va24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2016 Feb 9;6(2):213-227.

Karagiannis P, Iriguchi S, Kaneko S.

Reprogramming away from the exhausted T cell state. Semin Immunol. 2015 Nov 14.

Iriguchi S, Kikuchi N, Kaneko S, Noguchi E, Morishima Y, Matsuyama M, Yoh K, Takahashi S, Nakauchi H, Ishii Y.

T cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of lung macrophages in the lung. Blood. 2015 Jan 8;125(2):370-82. Epub 2014 Oct 27.

Mianagawa A, Kaneko S.

Rise of iPSCs as a cell source for adoptive immunotherapy. Human Cell. 2014 Apr;27(2):47-50.

Hirata S, Takayama N, Jono-Ohnishi R, Endo H, Nakamura S, Dohda T, Nishi M, Hamazaki Y, Ishii E, Kaneko S, Otsu M, Nakauchi H, Kunishima S, Eto K.

Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling. J Clin Invest. 2013 Sep 3;123(9):3802-14.

Kaneko S, Yamanaka S.

To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell. 2013 Apr 4;12(4):385-6.

Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Gotoh H, Zhu D, Nakayama K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H.

Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013 Jan 3;12(1):114-26.

Bondanza A, Hambach L, Aghai Z, Nijmeijer B, Kaneko S, Mastaglio S, Radrizzani M, Fleischhauer K, Ciceri F, Bordignon C, Bonini C, and Goulmy E.

IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. Blood. 117:6469-78, (2011)

Shimizu T, Sano S, Takayama N, Kaneko S(corresponding author), Eto K, Takeuchi Y, Nakauchi H.

Constitutive STAT5A activation enables erythropoiesis from human embryonic stem cell-derived primitive hematopoietic cells in the absence of erythropoietin. Kitasato Med. J. 41:42-49, (2011)

Kaneko S, Otsu M, and Nakauchi H.

Reprogramming of adult hematopoietic cells. Curr. Opinion. in Hematol. 17:271-5, (2010)

Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L, Radrizzani M, La Seta-Catamancio S, Provasi E, Mondino A, Nagasawa T, Fleischhauer K, Russo V, Traversari C, Ciceri F, Bordignon C, and Bonini C.

IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood. 113: 1006-15, (2009)

Sanuki S, Hamanaka S, Kaneko S, Otsu M, Karasawa S, Miyawaki A, Nakauchi H, Nagasawa T, and Onodera M.

A new red fluorescent protein that allows efficient marking of murine hematopoietic stem cells. J Gene Med 10: 9 65-71, (2008)

Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F and Bordignon C.

The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 15:1248-52, (2007)

Machino T, Okoshi Y, Kaneko S, Obara N, Mukai HY, Suzukawa K, Hasegawa Y, Yamashita Y, Mori N, Kojima H, and Nagasawa T.

Hepatosplenic alphabeta T-cell lymphoma successfully treated with allogeneic bone marrow transplantation. Bone Marrow Transplant 39:513-4, (2007)

Muto H, Kaneko S, Machino T, Okoshi Y, Mukai HY, Suzukawa K, Hasegawa Y, Imagawa S, Kojima H, Ishii Y, Hitomi S and Nagasawa T.

Quinupristin/dalfopristin and voriconazole controlled Staphylococcus epidermidis pneumonia and chronic necrotizing aspergillosis in a patient with severe lung degradation consequent to multiple treatments for Hodgkin’s lymphoma. J Infect Chemother 12:391-5, (2006)

Kaneko S, Nagasawa T, Nakauchi H and Onodera M.

An in vivo assay for retrovirally transduced human peripheral T lymphocytes using non-obese diabetic/ severe combined immunodeficiency mice. Exp. Hematol 33:35-41, (2005)

Shinagawa A, Kojima H, Berndt MC, Kaneko S, Suzukawa K, Hasegawa Y, Shigeta O, and Nagasawa T.

Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost. 93:889-96, (2005)

Kojima H, Hasegawa Y, Suzukawa K, Mukai HY, Kaneko S, Kobayashi T, Kamoshita M, Shinagawa A, Komeno T, Komatsu T, Mitsuhashi S, Kawachi Y, Yamashita Y, Mori N, and Nagasawa T.

Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification. Leuk Res. 28:1287-92, (2004)

Yoshida C, Kojima H, Ishigaki T, Katsura Y, Kaneko S, Suzukawa K, Hasegawa Y, Kawachi Y, Otsuka F, and Nagasawa T.

Association of pyoderma gangrenosum and sterile osteomyelitis in a patient having myelodysplastic syndrome with der(1;7)(q10;q10). Eur J Haematol. 72:149-53, (2004)

Suzuki A, Obi K, Urabe T, Hayakawa H, Yamada M, Kaneko S, Onodera M, Mizuno Y, and Mochizuki H.

Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein. J Neurochem. 82: 953-60, (2002)

Osawa M, Yamaguchi T, Nakamura Y, Kaneko S, Onodera M, Sawada K, Jegalian A, Wu H, Nakauchi H, and Iwama A.

Erythroid expansion mediated by the Gfi-1B zinc finger protein: role in normal hematopoiesis. Blood 100:2769-2777. (2002)

Iwama A, Osawa M, Hirasawa R, Uchiyama N, Kaneko S, Onodera M, Shibuya K, Shibuya A, Vinson C, Tenen DG, and Nakauchi H.

Reciprocal roles for CCAAT/enhancer binding protein (C/EBP) and PU.1 transcription factors in Langerhans cell commitment. J Exp Med 195:547-558, (2002)

Suzuki A, Zheng YY, Kaneko S, Onodera M, Fukao K, Nakauchi H, and Taniguchi H.

Clonal identification and Characterization of self-renewing pluripotent stem cells in the developing liver. J Cell Biol 156:173-184, (2002)

Kaneko S, Onodera M, Fujiki Y, Nagasawa T, and Nakauchi H.

The simplified retroviral vector GCsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in non-obese diabetic/severe combined immunodeficiency mice. Hum Gene Ther 12:35-44, (2001)

Yasukawa M, Hasegawa A, Sakai I, Ohminami H, Arai J, Kaneko S, Yakushijin Y, Maeyama K, Nakashima H, Arakaki R, and Fujita S.

Down-regulation of CXCR4 by human herpesvirus 6 (HHV-6) and HHV-7. J Immunol 162:5417-5422, (1999)

Ohminami H, Yasukawa M, Kaneko S, Yakushijin Y, Abe Y, Kasahara Y, Ishida Y, and Fujita S.

Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 93:925-935, (1999)

Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao S, Kishi K, Kubonishi I, Dan K, and Fujita S.

CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 92:3355-3361, (1998)

Kaneko S, Nagata M, Takemura H, Yuhara T, Akama T, Suzuki H, Yamane K, and Kashiwagi H.

Gelatinous transformation of bone marrow with pancytopenia in an emaciated patient with systemic lupus erythematosus. Jpn J Rheumatol 8:167-173, (1998)